Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

N 0923

Known as: N-0923 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
N-0923 is a non-ergot, dopaminergic D(2) agonist designed to be transdermally available. It has anti-parkinsonian effects when… Expand
Is this relevant?
2001
2001
N-0923 is a non-ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti-parkinsonian effects when… Expand
Is this relevant?
1999
1999
Nicotine, the soluble methyl ester of L-DOPA, and the D(2) agonist N-0923 were given alone and in combination im to five… Expand
Is this relevant?
1998
1998
N-0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist… Expand
Is this relevant?
1995
1995
The potencies for in vivo inhibition of substantia nigra pars compacta dopamine single cell firing were determined for… Expand
Is this relevant?
1994
1994
Certain aminotetralins are known to be potent dopamine D2 receptor agonists. N-0923, [-]2-(N-propyl-N-2-thienylethylamino)-5… Expand
Is this relevant?
1994
1994
The metabolism of the dopamine D2 agonist N-0923 was investigated by an in vitro isolated liver perfusion. Determining the… Expand
Is this relevant?
1993
1993
Using the hippocampal-slice preparation, we attempted to model operant conditioning in vitro by reinforcing pyramidal cell… Expand
Is this relevant?
1993
1993
A series of dopamine agonists were studied on contraversive circling behavior in seven 1-methyl-4-phenyl-1,2,3,6… Expand
Is this relevant?
1992
1992
The absorption of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxy-tetralin hydrochloride (1; N-0923… Expand
Is this relevant?